These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29773661)

  • 1. Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis.
    Lauer UM; Schell M; Beil J; Berchtold S; Koppenhöfer U; Glatzle J; Königsrainer A; Möhle R; Nann D; Fend F; Pfannenberg C; Bitzer M; Malek NP
    Clin Cancer Res; 2018 Sep; 24(18):4388-4398. PubMed ID: 29773661
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma.
    Mell LK; Brumund KT; Daniels GA; Advani SJ; Zakeri K; Wright ME; Onyeama SJ; Weisman RA; Sanghvi PR; Martin PJ; Szalay AA
    Clin Cancer Res; 2017 Oct; 23(19):5696-5702. PubMed ID: 28679776
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
    Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
    Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.
    Acuna SA; Ottolino-Perry K; Çako B; Tang N; Angarita FA; McCart JA
    Ann Surg Oncol; 2014 Jul; 21(7):2259-66. PubMed ID: 24719018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy using therapeutic and diagnostic recombinant oncolytic vaccinia virus GLV-1h153 for management of colorectal peritoneal carcinomatosis.
    Eveno C; Mojica K; Ady JW; Thorek DL; Longo V; Belin LJ; Gholami S; Johnsen C; Zanzonico P; Chen N; Yu T; Szalay AA; Fong Y
    Surgery; 2015 Feb; 157(2):331-7. PubMed ID: 25616946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional delivery of oncolytic vaccinia virus: it's time for clinical trials.
    Downs-Canner S; Bartlett DL
    Ann Surg Oncol; 2014 Jul; 21(7):2127-8. PubMed ID: 24682649
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis.
    Ottolino-Perry K; Tang N; Head R; Ng C; Arulanandam R; Angarita FA; Acuna SA; Chen Y; Bell J; Dacosta RS; McCart JA
    Int J Cancer; 2014 Feb; 134(3):717-30. PubMed ID: 23893655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma.
    Chintala NK; Choe JK; McGee E; Bellis R; Saini JK; Banerjee S; Moreira AL; Zauderer MG; Adusumilli PS; Rusch VW
    Front Immunol; 2023; 14():1112960. PubMed ID: 36875061
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Giehl E; Kosaka H; Liu Z; Feist M; Kammula US; Lotze MT; Ma C; Guo ZS; Bartlett DL
    Front Immunol; 2021; 12():610042. PubMed ID: 33679747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
    Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
    Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.
    Zeh HJ; Downs-Canner S; McCart JA; Guo ZS; Rao UN; Ramalingam L; Thorne SH; Jones HL; Kalinski P; Wieckowski E; O'Malley ME; Daneshmand M; Hu K; Bell JC; Hwang TH; Moon A; Breitbach CJ; Kirn DH; Bartlett DL
    Mol Ther; 2015 Jan; 23(1):202-14. PubMed ID: 25292189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.
    Thirunavukarasu P; Sathaiah M; Gorry MC; O'Malley ME; Ravindranathan R; Austin F; Thorne SH; Guo ZS; Bartlett DL
    Mol Ther; 2013 May; 21(5):1024-33. PubMed ID: 23439499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model.
    Koch J; Beil J; Berchtold S; Mönch D; Maaß A; Smirnow I; Schenk A; Carter ME; Kloker LD; Leibold T; Renner P; Dahlke MH; Lauer UM
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells.
    Minev BR; Lander E; Feller JF; Berman M; Greenwood BM; Minev I; Santidrian AF; Nguyen D; Draganov D; Killinc MO; Vyalkova A; Kesari S; McClay E; Carabulea G; Marincola FM; Butterfield LH; Szalay AA
    J Transl Med; 2019 Aug; 17(1):271. PubMed ID: 31426803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pronounced clinical response following the oncolytic vaccinia virus GL-ONC1 and chemotherapy in a heavily pretreated ovarian cancer patient.
    Mori KM; Giuliano PD; Lopez KL; King MM; Bohart R; Goldstein BH
    Anticancer Drugs; 2019 Nov; 30(10):1064-1066. PubMed ID: 31567308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.
    Guo ZS; Parimi V; O'Malley ME; Thirunavukarasu P; Sathaiah M; Austin F; Bartlett DL
    Gene Ther; 2010 Dec; 17(12):1465-75. PubMed ID: 20703311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
    de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
    BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas.
    Shivapurkar N; Wiethege T; Wistuba II; Milchgrub S; Muller KM; Gazdar AF
    Int J Cancer; 2000 Mar; 85(5):743-5. PubMed ID: 10699959
    [No Abstract]   [Full Text] [Related]  

  • 19. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer.
    Lee YS; Lee WS; Kim CW; Lee SJ; Yang H; Kong SJ; Ning J; Yang KM; Kang B; Kim WR; Chon HJ; Kim C
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
    Manyam M; Stephens AJ; Kennard JA; LeBlanc J; Ahmad S; Kendrick JE; Holloway RW
    Gynecol Oncol; 2021 Dec; 163(3):481-489. PubMed ID: 34686353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.